Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences Inc. (PLSE) Q4 2022 Earnings Call Transcript
08:41pm, Thursday, 30'th Mar 2023
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Trip Taylor – Investor Relations Kevin Danahy – President and Chief Executive
Pulse Biosciences, Inc. (PLSE) Q3 2022 Earnings Call Transcript
08:02pm, Thursday, 10'th Nov 2022
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin Danahy – Preside
Hot Penny Stocks To Watch As The Stock Market Crash Continues
02:30pm, Monday, 26'th Sep 2022
Hot penny stocks to add to your watch list this week. Is it time to buy?
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2022 Results - Earnings Call Transcript
07:40pm, Wednesday, 10'th Aug 2022
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Darrin Uecker - President an
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
06:48pm, Wednesday, 10'th Aug 2022
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 0% and 52.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
02:01pm, Friday, 13'th May 2022 Benzinga
Upgrades
B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46,
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
10:05pm, Wednesday, 11'th May 2022 Zacks Investment Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q1 2022 Results - Earnings Call Transcript
09:42pm, Wednesday, 11'th May 2022
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Offi
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
07:34pm, Wednesday, 11'th May 2022
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
10 Biggest Price Target Changes For Friday
11:35am, Friday, 01'st Apr 2022 Benzinga
Wells Fargo lowered the price target on General Motors Company (NYSE: GM) from $83 to $72. GM shares rose 0.8% to $44.10 in pre-market trading.
JMP Securities cut Taysha Gene Therapies, Inc. (NASD
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q4 2021 Results - Earnings Call Transcript
10:27pm, Thursday, 31'st Mar 2022
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q4 2021 Results - Earnings Call Transcript
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates
09:25pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 22% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates
06:48pm, Thursday, 31'st Mar 2022
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 22% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call for March 31, 2022
04:05pm, Monday, 21'st Mar 2022
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technol
NEW YORK, March 13, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive (the "Class Period"), of the important April 18, 2022…
